SLE is an autoimmune disease in which the body’s immune system mistakenly attacks its own healthy organs and tissue. If you have been diagnosed with moderate-to-severe SLE, you may qualify to participate in the Tulip SLE Study.
LN refers to kidney inflammation resulting from SLE. If you have been diagnosed with LN, you may qualify to participate in the Tulip LN Study.
At AstraZeneca, our goal is to develop new therapeutics that can help change peoples’ lives. While our scientific expertise drives the research, it is your contributions that ultimately help us deliver medicines that make a difference in our communities. Read More
Choosing to participate in clinical research study is an important personal decision and does involve certain risks and benefits. Please talk to your doctor if you are interested in joining a clinical trial. The below information can help you understand the basics of clinical research and in making informed decisions. Read More
The Tulip Program represents three clinical research studies that evaluate anifrolumab, an investigational drug that research suggests may work with the body's immune system to slow lupus disease activity. This series of studies represents AstraZeneca's commitment to finding a new drug for patients living with SLE or LN.
If lupus gets in the way of living your life, even with your current treatment, you may qualify to take part in this study.
To learn more about the Tulip Program, call 844-432-3887.
The Tulip Program is a series of clinical research studies evaluating an investigational drug for systemic lupus erythematosus (SLE) and lupus nephritis (LN).
By choosing to continue, you are confirming that you reside in the United States.